KR960701899A - 인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조 - Google Patents
인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조Info
- Publication number
- KR960701899A KR960701899A KR1019950704440A KR19950704440A KR960701899A KR 960701899 A KR960701899 A KR 960701899A KR 1019950704440 A KR1019950704440 A KR 1019950704440A KR 19950704440 A KR19950704440 A KR 19950704440A KR 960701899 A KR960701899 A KR 960701899A
- Authority
- KR
- South Korea
- Prior art keywords
- polypeptide
- human factor
- amino acid
- acid sequence
- protein complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000694 effects Effects 0.000 title claims abstract 7
- 102000001690 Factor VIII Human genes 0.000 title 1
- 108010054218 Factor VIII Proteins 0.000 title 1
- 102000007474 Multiprotein Complexes Human genes 0.000 title 1
- 108010085220 Multiprotein Complexes Proteins 0.000 title 1
- 229960000301 factor viii Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 28
- 229920001184 polypeptide Polymers 0.000 claims abstract 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 23
- 229940099816 human factor vii Drugs 0.000 claims abstract 11
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims abstract 9
- 102000057593 human F8 Human genes 0.000 claims abstract 9
- 229960000900 human factor viii Drugs 0.000 claims abstract 9
- 150000001413 amino acids Chemical class 0.000 claims abstract 8
- 125000006850 spacer group Chemical group 0.000 claims abstract 8
- 210000004027 cell Anatomy 0.000 claims abstract 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 238000000034 method Methods 0.000 claims 7
- 102100023804 Coagulation factor VII Human genes 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- 229940012413 factor vii Drugs 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 abstract 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 abstract 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
인간인자 Ⅷ:C A도메인에 실질적으로 상동인 첫번째 폴리펩티드, 인간인자 Ⅷ:C C도메인에 실질적으로 상동인 두번째 폴리펩티드를 코딩하는 첫번째와 두번째 발현카세트로 숙주세포를 형질변환시켜 진핵숙주 세포내에서 인자 Ⅷ:C활성을 갖는 재조합 단백질 복합체를 발현시킨다. 본 발명에서, 첫번째 폴리펩티드는 C-말단에 인간인가 Ⅷ:C B도메인 N-말단펩티드, 3-40 아미노산의 폴리펩티드 스페이서, 인간인자 Ⅷ:C B도 메인 C말단펩티드를 갖도록 연장될 수 있다. 두번째 폴리펩티드의 발현은 α1-항트립신 신호서열을 사용하여 개선시킨다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (19)
- 인간인자 Ⅷ:C활성을 갖는 단백질 복합체를 코딩하는 DNA구조체에 있어서, 상기 복합체는 인간인자 Ⅷ:C A도메인에 상동적인 첫번째 폴리펩티드가 인간인자 Ⅷ:C의 전체길이의 B도메인이 아닌 다른 폴리펩티드 스페이서에 의하여 인간인자 W:C의 C도메인에 상동적인 두번째 폴리펩티드에 연결된 것으로 이루어지는 것을 특징으로 하는 DNA 구조체.
- 제1항에 있어서, 상기 폴리펩티드 스페이서는 인간 Ig중사슬 힌지부위에 상동적인 펩티드를 함유하는 것을 특징으로 하는 DNA 구조체.
- 제2항에 있어서, 폴리펩티드 스페이서의 아미노산 서열은 Pro-Pro-Thr-Pro-Pro-Thr을 함유하는 것을 특징으로 하는 DNA 구조체.
- 제2항에 있어서, 상기의 첫번째 폴리펩티드는 인간인자 Ⅷ:C 아미노산 1-740의 아미노산 서열의 적어도 약 90%를 함유하고 상기의 두번째 폴리펩티드는 인간인자 Ⅷ:C 아미노산 1649-2332의 아미노산 서열의 적어도 약 90%를 함유하는 것을 특징으로 하는 DNA 구조체.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기의 DNA 구조체가 진핵숙주세포내에 존재할 때 상기 단백질 복합체의 발현을 일으킬 수 있는 조절서열을 추가로 함유하는 것을 특징으로 하는 DNA 구조체.
- 제5항의 DNA 구조체를 포함하는 진핵숙주세포.
- 제6항에 있어서, 상기의 숙주세포가 포유동물의 세포인 것을 특징으로 하는 진핵숙주세포.
- 인간인자 Ⅷ:C 활성을 갗는 재조합 단백질 복합체의 제조방법에 있어서, 상기 방법은 상기 DNA 구조체에 의해 코딩되는 단백질 복합체가 발현되는 조건하에서 제6항 또는 제7항의 숙주세포를 배양하는 것으로 이루어지는 것을 특징으로 하는 방법.
- 제8항에 있어서, 상기의 첫번째 및 두번째 폴리펩티드의 아미노산의 단지 약 5%만이 각각 인자 Ⅷ:CA 및 C도메인의 자연상태로 존재하는 아미노산 서열과 다른 것을 특징으로 하는 방법.
- 제8항에 있어서, 두번째 폴리펩티드의 아미노산 서열은 인간인자 Ⅷ:C의 아미노산 1649-2322의 아미노산 서열과 동일한 것을 특징으로 하는 방법.
- 제8항에 있어서, 첫번째 폴리펩티드의 아미노산 서열은 인간인자 Ⅷ:C의 아이노산 1-740의 아미노산서열과 동일한 것을 특징으로 하는 방법.
- 제8항에 있어서, 상기의 폴리펩티드 스페이서는 인간 Ig중사슬 힌지부위에 상동적인 펩티드를 함유하는 것을 특징으로 하는 방법.
- 인간인자 Ⅷ:C활성을 갖는 단백질 복합체에 있어서, 인간인자 Ⅷ:C의 A도메인에 상동적인 첫번째 폴리펩티드가 인간인자 Ⅷ:C의 전체길이의 B도메인이 아닌 다른 폴리펩티드 스페이서에 의하여 인간인자 Ⅷ:C의 C도메인에 상동적인 두번째 폴리펩티드에 연결된 것으로 이루어지는 것을 특징으로 하는 단백질 복합체.
- 제13항에 있어서, 상기의 폴리펩티드 스페이서는 인간 Ig중사슬 힌지부위에 상동적인 펩티드를 함유하는 것을 특징으로 하는 단백질 복합체.
- 제14항에 있어서, 폴리펩티드 스페이서의 아미노산 서열은 Pro-Pro-Thr-Pro-Pro-Thr을 함유하는 것을 특징으로 하는 단백질 복합체.
- 제13항에 있어서, 상기의 첫번째 폴리펩티드의 아미노산 서열의 아미노산의 단지 약 5%만이 인자 Ⅷ:C A도메인의 자연상태로 존재하는 아미노산 서열과 다른 것을 특징으로 단백질 복합체.
- 제13항에 있어서, 첫번째 폴리펩티드의 아미노산 서열은 인간인자 Ⅷ:C의 아미노산 1-740의 아미노산 서열과 동일한 것을 특징으로 단백질 복합체.
- 인간인자 Ⅷ:C활성을 갖지만 제37항의 방법에 의해 제조한 인간인자 Ⅷ:C의 B도메인의 진부 또는 일부가 결핍된 단백질 복합체.
- 인간인자 Ⅷ:C활성을 갖지만 제8항 내지 제12항 중 어느 한 항의 방법에 의해 제조한 인간인자 Ⅷ:C의 B도메인의 전부 또는 일부가 결핍된 단백질 복합체.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43863989A | 1989-11-17 | 1989-11-17 | |
| US438,639 | 1989-11-17 | ||
| PCT/DK1990/000291 WO1991007490A1 (en) | 1989-11-17 | 1990-11-15 | Protein complexes having factor viii:c activity and production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR960701899A true KR960701899A (ko) | 1996-03-28 |
Family
ID=23741420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950704440A Abandoned KR960701899A (ko) | 1989-11-17 | 1990-11-15 | 인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조 |
| KR1019920701170A Abandoned KR927003812A (ko) | 1989-11-17 | 1990-11-15 | 인자 viii:c 활성을 갖는 단백질 복합체 및 그의 제조 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920701170A Abandoned KR927003812A (ko) | 1989-11-17 | 1990-11-15 | 인자 viii:c 활성을 갖는 단백질 복합체 및 그의 제조 |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP0500734B1 (ko) |
| JP (3) | JP2865861B2 (ko) |
| KR (2) | KR960701899A (ko) |
| AT (1) | ATE163194T1 (ko) |
| AU (1) | AU656311B2 (ko) |
| CA (2) | CA2135744A1 (ko) |
| DE (1) | DE69032043T2 (ko) |
| DK (1) | DK0500734T3 (ko) |
| ES (1) | ES2112255T3 (ko) |
| FI (2) | FI922204A0 (ko) |
| GR (1) | GR3026176T3 (ko) |
| HU (2) | HUT70457A (ko) |
| IE (1) | IE904140A1 (ko) |
| IL (2) | IL96368A0 (ko) |
| NO (2) | NO921946L (ko) |
| NZ (1) | NZ236094A (ko) |
| PL (1) | PL167083B1 (ko) |
| PT (1) | PT95923B (ko) |
| SK (1) | SK130194A3 (ko) |
| WO (1) | WO1991007490A1 (ko) |
| YU (2) | YU218690A (ko) |
| ZA (1) | ZA909167B (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
| SE468050C (sv) * | 1991-03-15 | 1998-04-27 | Pharmacia & Upjohn Ab | Rekombinant derivat av human faktor VIII |
| CA2078721A1 (en) * | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
| DK53792D0 (da) * | 1992-04-24 | 1992-04-24 | Novo Nordisk As | Fremgangsmaade til fremstilling af proteiner |
| EP0768361A1 (en) * | 1995-10-16 | 1997-04-16 | Shin-Etsu Chemical Co., Ltd. | Liquid crystal composition and liquid crystal display element comprising the same |
| EP2202242A1 (en) | 1996-04-24 | 2010-06-30 | The Regents of The University of Michigan | Inactivation resistant factor VIII related applications |
| US8183344B2 (en) | 1996-04-24 | 2012-05-22 | University Of Michigan | Inactivation resistant factor VIII |
| GB2318732A (en) | 1996-11-01 | 1998-05-06 | Johnson & Johnson Medical | Wound healing compositions containing alpha-1-antitrypsin |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| ATE312176T1 (de) * | 2000-03-22 | 2005-12-15 | Octagene Gmbh | Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien |
| EP3211085B1 (en) | 2003-09-30 | 2021-03-31 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1707634A1 (en) | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
| DK2383346T3 (en) | 2005-04-07 | 2015-01-05 | Univ Pennsylvania | Modified AAVrh.64 capsids, compositions containing them and their uses |
| EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| WO2011095604A1 (en) | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US20130023033A1 (en) | 2010-03-29 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| ES2724800T3 (es) | 2011-02-17 | 2019-09-16 | Univ Pennsylvania | Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9 |
| US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| EP3283126B1 (en) | 2015-04-16 | 2019-11-06 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
| JP2023537070A (ja) | 2020-08-07 | 2023-08-30 | アミカス セラピューティックス インコーポレイテッド | 小胞を標的とするタンパク質及びその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652530A (en) | 1967-08-28 | 1972-03-28 | American Nat Red Cross | Antihemophilic factor prepared from blood plasma using polyethylene glycol |
| US3631018A (en) | 1970-05-01 | 1971-12-28 | Baxter Laboratories Inc | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate |
| US4069216A (en) | 1975-06-16 | 1978-01-17 | Edward Shanbrom, Inc. | Simplified methods for preparation of very high purity Factor VIII concentrate |
| AU577259B2 (en) * | 1982-08-13 | 1988-09-22 | Zymogenetics Inc. | Glycolytic promters for regulated protein expression protease inhibitor |
| JPH07106156B2 (ja) * | 1983-10-28 | 1995-11-15 | ジェネティックス、インスティチュ−ト | ファクタ−▲ｖｉｉｉ▼および関連生産物の製造 |
| ES8801674A1 (es) * | 1985-04-12 | 1988-02-16 | Genetics Inst | Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante. |
| FI98829C (fi) * | 1986-01-27 | 1997-08-25 | Chiron Corp | Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta |
| AU588965B2 (en) * | 1986-02-06 | 1989-09-28 | Alcatel Australia Limited | Telephone hook-switch |
-
1990
- 1990-11-15 AU AU67525/90A patent/AU656311B2/en not_active Ceased
- 1990-11-15 KR KR1019950704440A patent/KR960701899A/ko not_active Abandoned
- 1990-11-15 EP EP90917369A patent/EP0500734B1/en not_active Expired - Lifetime
- 1990-11-15 ES ES90917369T patent/ES2112255T3/es not_active Expired - Lifetime
- 1990-11-15 JP JP3500068A patent/JP2865861B2/ja not_active Expired - Lifetime
- 1990-11-15 DK DK90917369.2T patent/DK0500734T3/da active
- 1990-11-15 EP EP95107535A patent/EP0670332A3/en not_active Ceased
- 1990-11-15 NZ NZ236094A patent/NZ236094A/xx unknown
- 1990-11-15 CA CA002135744A patent/CA2135744A1/en not_active Abandoned
- 1990-11-15 KR KR1019920701170A patent/KR927003812A/ko not_active Abandoned
- 1990-11-15 HU HU9500546A patent/HUT70457A/hu unknown
- 1990-11-15 CA CA002068728A patent/CA2068728A1/en not_active Abandoned
- 1990-11-15 AT AT90917369T patent/ATE163194T1/de not_active IP Right Cessation
- 1990-11-15 HU HU9201629A patent/HUT64591A/hu unknown
- 1990-11-15 ZA ZA909167A patent/ZA909167B/xx unknown
- 1990-11-15 WO PCT/DK1990/000291 patent/WO1991007490A1/en active IP Right Grant
- 1990-11-15 DE DE69032043T patent/DE69032043T2/de not_active Expired - Lifetime
- 1990-11-16 YU YU218690A patent/YU218690A/sh unknown
- 1990-11-16 PT PT95923A patent/PT95923B/pt not_active IP Right Cessation
- 1990-11-16 IL IL96368A patent/IL96368A0/xx unknown
- 1990-11-16 PL PL90287807A patent/PL167083B1/pl unknown
- 1990-11-16 IE IE414090A patent/IE904140A1/en not_active Application Discontinuation
-
1992
- 1992-05-14 FI FI922204A patent/FI922204A0/fi not_active Application Discontinuation
- 1992-05-15 NO NO92921946A patent/NO921946L/no unknown
-
1994
- 1994-10-14 IL IL11130494A patent/IL111304A0/xx unknown
- 1994-10-18 NO NO943949A patent/NO943949D0/no unknown
- 1994-10-19 FI FI944903A patent/FI944903A0/fi unknown
- 1994-10-26 SK SK1301-94A patent/SK130194A3/sk unknown
- 1994-12-28 YU YU78194A patent/YU78194A/sh unknown
-
1995
- 1995-06-13 JP JP7146581A patent/JP2771129B2/ja not_active Expired - Lifetime
-
1998
- 1998-02-18 GR GR980400352T patent/GR3026176T3/el unknown
- 1998-08-24 JP JP10237850A patent/JPH11130800A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960701899A (ko) | 인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조 | |
| Sage et al. | Structural studies on human type IV collagen. | |
| Hatzfeld et al. | Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides. | |
| ATE146219T1 (de) | Polypeptid | |
| DE59711812D1 (de) | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden | |
| CA2359242A1 (en) | Growth differentiation factor inhibitors and uses therefor | |
| Jimenez et al. | Identification of two new collagen α-chains in extracts of lathyritic chick embryo tendons | |
| KR910021477A (ko) | 인체 단백질 c의 글리코실화 돌연변이체의 발현을 위한 벡터 및 화합물 | |
| ATE197611T1 (de) | Screeningverfahren von morphogenischen proteinen | |
| AU7873798A (en) | N-terminally extended proteins expressed in yeast | |
| DE69030920D1 (de) | Verfahren zur herstellung von pai-2 | |
| KR890013178A (ko) | 인간의 콜로니 자극인자 | |
| DE69634757D1 (de) | Vektor zur expression von n-terminal verlängerten proteinen in hefezellen | |
| DE60029791D1 (de) | Rezeptor eines neurotrophen faktors (gfr-alpha-4) | |
| WO1995021916A3 (en) | Pp32: a newly identified cd45-associated protein | |
| Chauvet et al. | Characterization of porcine MSEL-neurophysin | |
| Bolivar | Immunological crossreactivity of Paramecium surface antigens: conformational differences account for cell surface specificity. | |
| ATE277176T1 (de) | Faltende proteine | |
| DE60043664D1 (de) | Dungen davon | |
| KR930023459A (ko) | 유전분체 전구체 돌연변이 단백질을 암호하는 핵산분자, 이를 포함하는 벡터 및 세포, 이에 의해 생산되는 재조합 폴리펩티드 및 폴리펩티드의 존재를 탐지하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 19951011 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19951011 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19980629 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19981222 |
|
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |